We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
- Authors
Martin, M A; Klein, T E; Dong, B J; Pirmohamed, M; Haas, D W; Kroetz, D L; Clinical Pharmacogenetics Implementation Consortium
- Abstract
Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.
- Publication
Clinical pharmacology and therapeutics, 2012, Vol 91, Issue 4, p734
- ISSN
1532-6535
- Publication type
Journal Article
- DOI
10.1038/clpt.2011.355